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Abstract
In the surgical treatment of full-thickness macular holes good results have been published with the combination of 
vitrectomy, gas and application of Transforming Growth Factor /? 2. Other authors report a 73% success rate in 
closing a full-thickness macular hole after vitrectomy and gas tamponade alone. We used, in addition to vitrectomy 
and gas tamponade, a tissue glue to stimulate adhesion of the elevated cuff of neurosensory retina surrounding a 
full-thickness macular hole and to close to hole itself. A total of 15 eyes of 13 patients (3 men, 10 women), with 
stage 3 and 4 macular holes were operated. All of the 13 uncomplicated cases showed complete closure of the 
macular hole. In one case (8%) the visual acuity decreased one line in spite of a funduscopically closed hole, and 
in two cases (16%) visual acuity remained the same despite closure. Increased visual acuity was seen in ten cases 
(76%), eight of which improved more than two lines.
Introduction
Several techniques have been proposed for the treat­
ment of full-thickness macular holes. Vitrectomy with 
removal of all premacular cortical vitreous and gas 
tamponade [1] has been published as a means to close 
a macular hole. Our own results with this technique, 
however, were unsatisfactory (unpublished data). In 
addition to pars plana vitrectomy with removal of 
premacular cortical vitreous, transforming growth fac­
tor (TGF ¡3 2) has been advocated [2, 3]. Others have 
used autologous serum to this purpose [4].
In an attempt to permanently close full-thickness 
macular holes, we used a tissue glue (Tissucol Duo 
500, Immuno AG, Vienna, Austria) which is a biologi­
cal two component fibrin sealant prepared from pooled 
human plasma. The main active components are fib­
rinogen, fibronectin, factor 8, plasminogen and throm­
bin. Applied on tissue this gives a temporary solidified 
sealant which is completely absorbed in approximately 
one week. Since the glue only can be applied on a mac­
ula devoid of vitreous, complete removal of all poste­
rior cortical vitreous is essential. Specially in younger 
patients this can be difficult to achieve. In two cas- 
es proliferative vitreoretinopathy (PVR) occurred with
traction retinal detachment, which was treated accord­
ingly. Whether this is a direct result of the use of the 
intraocular glue and/or the amount of glue has not been 
clearly established.
Patients and methods
All patients had a complete ophthalmologic examina­
tion, including best corrected Snellen distance visual 
acuity, slit-lamp biomicroscopy, applanation tonome­
try and slit-lamp biomicroscopic evaluation with the 
Golmann contact lens.
Our surgical technique consists of a pars plana vit­
rectomy with meticulous removal of all premacular 
cortical vitreous. With either a flute needle and/or vitre­
ous pick, a posterior vitreous detachment was created. 
Any epiretinal membranes, if present, were removed. 
A gas-fluid exchange was performed, followed by the 
swift application of a drop of the tissue glue on the 
posterior pole. The air was exchanged for a 16% C3F8 
mixture. The application of a drop of the glue, approx­
imately 50 /¿l, with a blunt 20 gauge needle, has to 
be quick in order to prevent the glue from sticking 
to the needle. Tissucol is a biological two component
Fig. 1. Fundus photography on the first postoperative day demonstrates a gas-filled vitreous cavity with a mass of white tissue glue present 
over the posterior pole and macula.
sealant, the components come deep frozen, in preload­
ed syringes, and have to be defrosted prior to use. We 
defrost the Tissucol 30 minutes before use and warm it 
up to 37° C. The components are mixed in the needle 
during application.
This results in a viscous solution that quickly sets 
to form an elastic white mass, which firmly adheres to 
tissue. This process simulates the key features of the 
physiological coagulation process and is used to seal 
or glue tissue and to support wound healing. In the 
course of wound healing the solidified sealant is com­
pletely absorbed. Since the solidified sealant reaches 
its ultimate strength after about 2 hours, we positioned 
the patient strictly supine until the next day. After that 
we instruct the patient to keep a face down position for 
one week. The duration of the white mass of tissue glue 
was five to ten days, the disappearance showed gradual 
thinning combined with the appearance of irregulari­
ties at the edge of the mass.
Results
A total of 15 eyes of 13 patients (3 men, 10 women), 
with stage 3 and 4 macular holes were operated. The 
ages ranged from 35 to 81 years, mean 64 years. The 
duration of preoperative visual complaints ranged from 
1 to 36 months, mean 7.5 months. Preoperative visual 
acuity ranged from 20/60 to 5/200 (mean: 20/100). 
Fifteen eyes had a follow up of three month or more, 
postoperative visual acuity ranged from 20/30 to 5/200 
(mean 20/60). In our first series of 15 eyes two cases 
developed of proliferative vitreoretinopathy in the first 
postoperative week.
All of the 13 uncomplicated cases showed a com­
plete closure of the macular hole. In one case (8%) 
the visual acuity decreased one line in spite of a fun- 
duscopically closed hole, in two cases (16%) v is u a l  
acuity remained the same despite closure, an increase 
of visual acuity was seen in ten cases (76%), eight of 
which increased more than two lines.
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Fig. 2. On the left is a preoperative fundus photograph of 
full-thickness macular hole with a surrounding cuff of subretina! 
fluid. Two months postoperatively (on the right), the macular hole is 
closed and the previous cuff of subretinal fluid is completely reab­
sorbed,
Discussion
Tissucol is prepared from pooled human plasma. To 
minimize the risk of viral infection only plasma units 
are used which are non-reactive in tests for HBs- 
antigen as well as for HIV-1-, HIY-2-. Autologous 
serum, autologous plasma and platelets have been 
reported as an adjunct in macular hole surgery; how­
ever, these techniques all require handling with blood 
and therefore bear a risk of bacterial infection, Macu­
lar holes appear most frequently in women in the sixth 
decade.
In most cases it is a unilateral disease [5]. Full- 
thickness macular holes usually result in a reduction of 
visual acuity to a level between 20/200 and 20/80 [6]. 
In our series we found bilateral macular hole in 28% of 
cases. Spontaneous resolution of early stages of macu­
lar hole has been reported [7], but this has not been seen 
in holes of longer duration. Separation of the posterior 
vitreous with release of vitreoretinal traction is thought 
to prevent the progression of early stages of macular 
hole. Nevertheless it is thought that a posterior vitre­
ous detachment can prevent the progression from an 
impending to a full-thickness macular hole. According 
to Wendel et al., vitrectomy with relief of all tangen­
tial traction and retinal tamponade with intraocular gas 
can provide meaningful improvement of visual acuity 
[8].
Since our experiences with vitrectomy and gas tam­
ponade alone were unsatisfactory in permanently clos­
ing full-thickness macular holes, perhaps in part due 
to incomplete removal of all tangential traction and 
possibly insufficient compliance with the postopera­
tive face-down positioning, we decided to use a tis­
sue glue. Because TGF beta 2 was not commercially 
available for clinical use, we decided to use Tissucol* 
Coleman and co-authors have reported positive results 
with biologic glue in the treatment of giant retinal tears 
and macular holes [9]. In their animal model tissue 
glue was injected underneath artificially detached reti­
na. They found circumscribed chorioretinal adhesion 
at the injection site of retroretinal glue. Later they used 
tissue glue in five patients with a macular hole and two 
patients with giant tears.
We speculate that a similar chorioretinal adhesion 
may occur when tissue glue is placed on a macular 
hole instead of under the edge of the retina and in this 
manner stimulates both closure of the macular hole and 
adhesion of the cuff of subretinal fluid surrounding the 
hole.
During surgery it is essential to induce a posteri­
or vitreous detachment before application of the tissue 
glue, since the glue has to stick to the macula. Especial­
ly in relatively young patients, creating a posterior vit­
reous detachment and removal of all posterior vitreous 
can be difficult. Either active suction with a silicone- 
tipped flute needle or peeling with a bent sharp needle 
was tried in every case to create a posterior vitreous 
detachment and remove all remaining vitreous. Three 
months postoperatively we could not detect any sign 
of a full thickness macular hole in any patient. The sur­
rounding rim had disappeared and we could no longer 
identify remnants of the edge of the macular hole.
Generally, postoperative closure of macular holes, 
specially those with flattened and unidentifiable edges, 
will show a smaller scotoma and higher visual acuity 
than preoperatively. Most likely the glue will stimu­
late chorioretinal adhesion of the retina surrounding 
the hole. Although it is possible that tissue glue will 
result in the discrete macular epiretinal, or preretinal 
membrane at the site of the preexisting hole, we did 
not observe such occurrence in any of our patients. 
In early cases however, proliferative vitreoretinopathy 
did develop shortly after the operation. In later cases, 
we have not experienced this complication, which may 
have been related to the completeness of the vitrecto-
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my or experience with tissue glue application. Since 
any manipulation of the vitreous can induce PVR, vit­
rectomy, application of a glue and gas tamponade are 
definite risk factors. We feel that the amount of applied 
glue is related to this risk, so we have reduced the 
amount of glue and improved the application methods, 
and in doing so, shortened operation time.
Since there was great heterogeneity in the pre­
sented group of macular holes regarding the type of 
hole, duration of symptoms, myopia, size of the hole 
and intraoperative difficulties with respect to complete 
removal of all vitreous and inducing a posterior vit­
reous detachment, the importance of these respective 
parameters has to be further studied. The first results 
indicate that adding tissue glue to the surgical proce­
dure can enhance the anatomical and functional out­
come of surgery significantly.
Longer follow up is needed to determine the final 
place of tissue glue in the treatment of full thickness 
macular holes.
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